Success Metrics

Clinical Success Rate
50.0%

Based on 4 completed trials

Completion Rate
50%(4/8)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
4(44%)

Phase Distribution

Ph phase_1
4
44%
Ph early_phase_1
1
11%
Ph phase_2
4
44%

Phase Distribution

5

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
4(44.4%)
Phase 2Efficacy & side effects
4(44.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

44.4%

4 of 9 finished

Non-Completion Rate

55.6%

5 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(4)
Terminated(5)

Detailed Status

Terminated4
Completed4
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (11.1%)
Phase 14 (44.4%)
Phase 24 (44.4%)

Trials by Status

terminated444%
withdrawn111%
completed444%

Recent Activity

0 active trials
Showing 5 of 9
completedphase_1

Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function

NCT00997399
completedphase_1

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

NCT00946647
terminatedphase_2

Study of Panobinostat in Patients With Neuroendocrine Tumors

NCT00985946
completedphase_1

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

NCT01111526
withdrawnearly_phase_1

ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer

NCT00993642
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT00997399Phase 1

Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function

Completed
NCT00946647Phase 1

A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).

Completed
NCT00985946Phase 2

Study of Panobinostat in Patients With Neuroendocrine Tumors

Terminated
NCT01111526Phase 1

Histone Deacetylase Inhibitor LBH589 in Addition to Corticosteroids in Patients With Acute Graft Versus Host Disease (GVHD)

Completed
NCT00993642Early Phase 1

ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer

Withdrawn
NCT00777335Phase 2

Study of Panobinostat Monotherapy in Women With v-ERB-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) Positive Locally Recurrent or Metastatic Breast Cancer

Terminated
NCT00738751Phase 1

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

Completed
NCT01528501Phase 2

Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)

Terminated
NCT00699296Phase 2

Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

Terminated

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9